Loading peptide profile…
Loading peptide profile…
Healing Category
THE GUT SEALER
AT-1001; Larazotide Acetate
Larazotide acetate is an experimental eight-amino acid peptide studied alongside a gluten-free diet in celiac disease. Phase 3 testing ended early for futility in 2022, and a meta-analysis of four randomized trials found no significant effect on a gut permeability measure. It is not FDA-approved.
People with celiac disease · Those with leaky gut syndrome · Crohn's disease patients · Anyone with food sensitivities · People with IBS
Not FDA approved, research use onlyHow we review these guides15 research sources
Proposed to counter zonulin, a hormone thought to loosen junctions between gut cells. The idea has not produced a confirmed clinical benefit.
Designed to close junctions between gut cells. A meta-analysis of four randomized trials found no significant change in a lactulose-to-mannitol permeability test.
Reduces immune activation from leaked antigens
Larazotide is a synthetic peptide containing eight amino acids. Its discovery came from screening synthetic peptides related to Vibrio cholerae, rather than isolating a human hormone. Alba Therapeutics researchers subsequently described it in epithelial-cell experiments published in 2012, providing part of the laboratory history behind the compound.
[Larazotide discovery background in the 2015 trial report](https://pmc.ncbi.nlm.nih.gov/articles/PMC4446229/)
[Alba Therapeutics laboratory study, 2012](https://pubmed.ncbi.nlm.nih.gov/22401910/)
No. This profile records Larazotide as not FDA approved and for research use only. Review the regulatory and source details on this page for the current context.
This guide links to 15 curated or current research sources. Inspect the research section and the citations beneath the research answers for their supporting sources.
Review the Larazotide research sourcesWe don't list specific side effects for Larazotide.
Larazotide has an editorial safety grade of A (Excellent Safety). Human data come from celiac disease trials, where adverse events were similar to placebo. No safety data cover gray-market use. Safety depends on dose, sourcing, health history and medical supervision, so this page does not call it safe for personal use.
Larazotide, a synthetic octapeptide, acts on tight junctions by blocking zonulin receptors. It is described as a tight junction regulator that acts in the intestine. By blocking these receptors, larazotide reduces tight junction permeability and prevents their breakdown, which limits antigen trafficking.
The source lists larazotide acetate as another name for larazotide, also written AT1001, and describes it as a zonulin octapeptide inhibitor. A separate statement describes the form larazotide acetate as a zonulin inhibitor. The facts give no difference between the two names, so they are presented as the same compound.
Market evidence
We found certificates from most of the Larazotide vendors we track. Based on the certificates our crawler found; vendors may publish more than we index. Research on this page describes the molecule. Vendor certificates concern particular market samples or batches; they do not change the research evidence or establish clinical safety, sterility, or suitability for use.
The clinic network
Request a free connection to a peptide clinic, by telehealth or in person. A licensed clinician decides whether any treatment is right for you. What peptide therapy involves
A pancreatic peptide studied in animals and a human report
from $1.50/mg · 8 vendorsNº 006 / 006NNMT-blocking small molecule tested in cells and obese mice
from $0.90/mg · 143 vendorsNº 001 / 006Synthetic gastric peptide studied almost entirely in animals
from $1.10/mg · 252 vendorsNº 002 / 006An alpha-MSH fragment studied in experimental inflammation
from $1.80/mg · 160 vendorsNº 003 / 006Mitochondrial peptide studied in mice and cells, not FDA-approved
from $1.20/mg · 236 vendorsNº 004 / 006Cell coenzyme studied in people mostly through precursors NR and NMN
from $0.03/mg · 201 vendorsNº 005 / 006